Literature DB >> 8574025

Pretreatment of human myocardium with adenosine during open heart surgery.

H T Lee1, R J LaFaro, G E Reed.   

Abstract

BACKGROUND: Depressed myocardial performance after cardiac surgery can be contributed to ischemic reperfusion injury (IRI) incurred during and following the cardiopulmonary bypass (CPB). Myocardial preconditioning (PC) achieved by brief ischemia and subsequent reperfusion appears to be a clinically useful method of improved cardiac protection during surgery involving CPB by retarding IRI. Based on animal studies, activation of cardiac adenosine (ADO) receptors prior to the prolonged ischemic period appears to mimic this PC phenomenon. AIMS AND METHODS: We investigated whether the human myocardial PC can be mimicked with ADO in the setting of the coronary artery bypass graft (CABG). The specific proposed objective of this study was to determine whether ADO infusion just prior to starting the CPB can improve post-CPB myocardial hemodynamics. Patients undergoing elective CABG with poor ventricular function (ejection fraction approximately 30%), and with at least three-vessel disease were selected for this study (n = 7 ADO, and n = 7 control).
RESULTS: Our results show that ADO infusion (250-350 micrograms/kg X 10 min) just prior to CPB resulted in an immediately improved postbypass cardiac index (CI) in the OR (CI increase of 41.5% +/- 11.1% for ADO vs 9.7% +/- 6.0% for control, p < 0.05). Forty hours postoperatively in the intensive care unit, ADO patients had improved CI (3.3 +/- 0.2 L/min per m2 for ADO, vs 2.6 +/- 4 L/min per m2 for control, p < 0.05). ADO patients maintained lowered resting heart rate (90 +/- 6 for ADO, vs 108 +/- 4 for control, p < 0.05) 40 hours after surgery. ADO patients also released significantly less CPK during the first 24 hours of the postoperative period.
CONCLUSION: Based on these measurements, ADO pretreated patients had improved ventricular performance postoperatively. It also appears that ADO pretreatment results in lowered postoperative myocardial energy demand and less myocellular injury during CPB. To our knowledge, this is the first study to demonstrate that human myocardium can be hemodynamically improved with ADO pretreatment, and may be protected against IRI incurred during and following the CPB. We believe that a cardiac surgeon may now have the unique opportunity to confer myocardial protection during and after a cardiac surgical procedure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8574025     DOI: 10.1111/j.1540-8191.1995.tb00657.x

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  9 in total

Review 1.  Therapeutic potential of ischaemic preconditioning.

Authors:  R J Edwards; A T Saurin; R D Rakhit; M S Marber
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

Review 2.  Cardioprotection during cardiac surgery.

Authors:  Derek J Hausenloy; Edney Boston-Griffiths; Derek M Yellon
Journal:  Cardiovasc Res       Date:  2012-03-22       Impact factor: 10.787

3.  Adenosine in cold blood cardioplegia--a placebo-controlled study.

Authors:  Anders Ahlsson; Claudio Sobrosa; Lennart Kaijser; Eva Jansson; Vollmer Bomfim
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-11-15

4.  Adenosine myocardial protection: preliminary results of a phase II clinical trial.

Authors:  R M Mentzer; V Birjiniuk; S Khuri; J E Lowe; P S Rahko; R D Weisel; H A Wellons; M L Barker; R D Lasley
Journal:  Ann Surg       Date:  1999-05       Impact factor: 12.969

5.  Intravenous adenosine protects the myocardium primarily by activation of a neurogenic pathway.

Authors:  Olivier C Manintveld; Maaike te Lintel Hekkert; Elisabeth Keijzer; Pieter D Verdouw; Dirk J Duncker
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

6.  Chronic lower extremity ischemia: a human model of ischemic tolerance.

Authors:  Amit Badhwar; Thomas L Forbes; Marge B Lovell; Alison A Dungey; Sarah D McCarter; Jeffrey R Scott; Guy DeRose; Kenneth A Harris; Richard F Potter
Journal:  Can J Surg       Date:  2004-10       Impact factor: 2.089

Review 7.  Adjuvant cardioprotection in cardiac surgery: update.

Authors:  Robert Wagner; Pavel Piler; Zufar Gabbasov; Junko Maruyama; Kazuo Maruyama; Jiri Nicovsky; Peter Kruzliak
Journal:  Biomed Res Int       Date:  2014-08-19       Impact factor: 3.411

8.  The influence of rapamycin on the early cardioprotective effect of hypoxic preconditioning on cardiomyocytes.

Authors:  Jiang Wang; YiLiyaer Maimaitili; Hong Zheng; Jin Yu; Hai Guo; Hai-Ping Ma; Chun-Ling Chen
Journal:  Arch Med Sci       Date:  2016-05-05       Impact factor: 3.318

9.  Fingolimod Plays Role in Attenuation of Myocardial Injury Related to Experimental Model of Cardiac Arrest and Extracorporeal Life Support Resuscitation.

Authors:  Naseer Ahmed; Abid H Laghari; Bashar AlBkhoor; Sobia Tabassum; Sultan Ayoub Meo; Nazeer Muhammad; Daniele Linardi; Abeer A Al-Masri; Guido Fumagalli; Giovanni Battista Luciani; Giuseppe Faggian; Alessio Rungatscher
Journal:  Int J Mol Sci       Date:  2019-12-11       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.